Johnson & Johnson MedTech acquired Laminar, a Santa Rosa, California-based medical device company, for $400M.
The upfront payment is subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond.
Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment.
Led by Randy Lashinski, President and CEO, Laminar is a medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), which is an approved therapy for reducing the risk of thromboembolism in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy but have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants. This is particularly important for the nearly 40% of AFib patients who cannot tolerate long-term blood thinners. Laminar recently received FDA approval for the U.S. pivotal study, which will begin enrollment in early 2024.
Led by Jasmina Brooks, President, Biosense Webster specializes in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of Johnson & JohnsonMedTech, the medical-technology company is headquartered in Irvine, California, and works to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care.
FinSMEs
01/12/2023